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The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow The detection of JAK2 V617F somatic mutation has greatly enhanced our understanding of the pathogenesis of the bcr/ablnegative chronic myeloproliferative disorders (MPD). An increased sensitivity to erythropoietin and growth factor independence is reported in the presence of the mutation. [1] [2] [3] Four independent groups recently report JAK2 V617F mutation in the majority of patients with polycythaemia vera and up to 50% of essential thrombocythaemia and idiopathic myelofibrosis. [1] [2] [3] [4] An increased incidence of thrombosis, haemorrhage and fibrotic transformation in the presence of the mutant allele is reported. 3 Larger studies are however required to elicit the true prognostic significance of the mutation.
The finding of JAK2 V617F mutation outside of the classical MPDs is uncommon with reports of low incidence in chronic myelomonocytic leukaemia, atypical chronic myeloid leukaemia, hypereosinophilic syndrome and chronic neutrophilic leukaemia. 5 The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal haematopoietic stem cell disorders characterised by peripheral blood cytopenias, ineffective erythropoiesis and increased apoptosis. The 5qÀ syndrome is a subgroup of MDS characterised by an interstitial deletion of the long arm of chromosome 5(q31-q33) with macrocytic anaemia, normal or elevated platelet count, hypolobated megakaryocytes and associated with a favourable prognosis. However, cases presenting with 5q deletion and marked elevation of the platelet count in association with a hypercellular bone marrow display characteristics more suggestive of an overlap syndrome (MDS/ MPD).
We analysed 97 patients from six European centres known to have a diagnosis of MDS and deletion, 5q abnormality for the presence of JAK2 V617F mutation. Isolated deletion of 5q was detected in 81/97 cases, whereas additional cytogenetic abnormalities were noted in 16/97. The diagnosis of MDS was based on the World Health Organization Classification. A summary of patient characteristics is outlined in Table 1 . Ethical approval was obtained before study commencement. Samples for analysis were obtained from archived bone marrow aspirate slides, archived cytogenetic samples or peripheral blood.
The mutant JAK2 allele was detected using an allele-specificpolymerase chain reaction (AS-PCR). 4, 6, 7 The presence of the mutation and ratio of mutant to wild-type JAK2 allele was confirmed in 2/6 mutant cases using pyrosequencing. Polymerase chain reaction products were generated using AS-PCR primer sequences. Sequences were read from a reverse sequencing primer 5 0 -TCTCGTCTCCACAGA-3 0 . Pyrosequencing reactions were run on a Biotage PSQ HS 96 pyrosequencer.
In a patient with JAK2 mutation, cells from bone aspirate were subjected to progenitor cell culture (CFU-GM-and BFU-Ederived colonies) or subfractionated into CD34 þ ve cells, followed by molecular analysis. Peripheral blood from the same case was also subfractionated into CD14, CD15, CD3 and CD19 þ cells using antigen-specific microbeads followed by selection using the AutoMacs cell separator Milteny. In the case of progenitor cultures, PCR was performed directly on the cells without prior DNA purification. DNA was extracted from subfractionated cells using Charge Switch reagents (Invitrogen, Inchinnan Business Park, Fountain Drive, Paisley, UK). All DNA extraction and cell separation kits were used according to the manufacturer's instructions.
Samples were processed in accordance with standard cytogenetic methods. CD34 þ cells were probed for 5q using the Vysis LSI EGR1 (5q31), spectrum orange D5S23 and spectrum green D5S721 probe, according to the manufacturer's instructions (Abbot Laboratories). 100K Affymetrix SNP analysis of DNA extracted from CD34-positive cells was performed using standard methods (Affymetrix, Santa Clara, CA, USA). Data were analysed using DChipSNP software http://biosun1.harvard.edu/ complab/dchip/.
The JAK2 V617F mutation was detected in 6/97 (6.2%) of the samples analysed. All six mutant cases had a diagnosis of 5qÀ syndrome (isolated deletion 5q) with stable disease in 5/6 and RAEB-I in 1/6 at a median follow-up of 53 months (range 2-192 months). On analysis of the haemoglobin (Hb), platelet count and total white cell count (WCC) in the JAK2 mutant versus wild-type groups, no difference in median Hb (9.0 vs 8.7 g/dl, P ¼ 0.272), a trend towards a higher platelet count (475 vs 250 Â 10 9 /l, P ¼ 0.15) and a significant elevation in WCC (5.21 vs 4.45 Â 10 9 /l, P ¼ 0.012) was observed in the JAK2 mutant cases. In two JAK2 mutant cases, thrombocytosis warranted treatment with hydroxyurea or anagrelide. In addition to the higher indices, all six mutant cases were associated with a moderate/marked increase in bone marrow cellularity with evidence of granulocytic hyperplasia in 3/6, eosinophilia in 1/6 and dysplastic features in keeping with MDS in all six cases (Figure 1) . Regular blood transfusion support was required in 4/6 JAK2 mutant cases with recombinant erythropoietin administered in two cases with no response.The V617F mutation was detected in CD34, CD14, CD15 and CD61 þ cells, but was absent in CD3 and CD19 þ cells. In addition, pyrosequencing, affymetrix 100K SNP analysis and fluorescence in situ hybridisation (FISH) analysis were performed on the same CD34 þ cell sample.
Fluorescence in situ hybridisation analysis showed the 5qÀ abnormality in 91% (137/150) of CD34 þ cells. The frequency of the JAK2 allele within this same population is 20%. Microarray 100K SNP analysis did not reveal either uniparental disomy (UPD) or loss of heterozygosity (LOH) at the JAK2 locus. The relatively low percentage of the mutant JAK2 allele call in purified cell lineages and the lack of LOH or UPD support the notion that this patient is heterozygous for the mutant JAK2 V617F allele. We can also conclude that the 5qÀ and JAK2 V617F mutant clones must overlap, that is, some cells that contain the 5qÀ abnormality must also contain the JAK2 mutation. However, the data do not demonstrate that all 5qÀ cells are also JAK2 V617F mutant.
BFU-E-and CFU-GM-derived colonies were grown from the bone marrow of the above case. CFU-GM-derived colonies were more numerous than BFU-E-derived colonies. A total of 14 colonies were picked for AS-PCR, only 8/14 colonies gave analysable AS-PCR data with 2/3 BFU-E colonies and 4/8 CFU-GM colonies containing the JAK2 mutation. The finding of JAK2 mutation in CD34 þ cells, BFU-E colonies and CFU-GM colonies supports the notion that JAK2 mutation arises from a Figure 1 (a) Bone marrow trephine image demonstrating increased cellularity in patient with JAK2 V617F mutation and 5qÀ syndrome ( Â 10 magnification). (b) Bone marrow trephine demonstrating abnormal megakaryocyte morphology, hypercellularity and excess haemosiderin pigment in a transfusion-dependent case of JAK2 V617F mutation and 5qÀ syndrome ( Â 40 magnification). Letters to the Editor pluripotent stem cell. However, the fact that not all CD34-positive or all BFU-E or CFU-GM colonies are positive for V617F suggests that the bone marrow of this patient is not monoclonal with respect to the JAK2 mutation. In summary, the JAK2 V617F mutation was detected in a cohort of patients with 5qÀ syndrome and a hypercellular marrow. Despite no statistical difference, a higher median platelet count was observed in the mutant cases with 50% (3/6) showing a platelet count 4700 Â 10 9 /l compared with only 3% (3/91) in the wild-type cases. The lack of clinical response to erythropoietin in the two cases described fails to support previous in vitro studies documenting hypersensitivity to erythropoietin in the presence of the mutation.
Whether the JAK2 mutation occurs as an early or late event during the disease course is unclear. We detected the JAK2 mutation both at time of diagnosis and at a follow-up of 132 months in one case analysed, suggesting that the mutation occurred as an early event. Longer follow-up is however necessary to determine the prognostic significance of JAK2 mutation and in particular, whether these cases will show favourable response to lenalidomide as previously demonstrated in 5qÀ chromosomal abnormalities. 8 
